Glen Eagle Advisors’s Cidara Therapeutics CDTX Stock Holding History

Glen Eagle Advisors’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-5	Closed	-$520	–	714
2018 Q2	$520	Hold	5	–	–	﹤0.01%	673
2018 Q1	$400	Hold	5	–	–	﹤0.01%	669
2017 Q4	$680	Hold	5	–	–	﹤0.01%	620
2017 Q3	$810	Hold	5	–	–	﹤0.01%	616
2017 Q2	$750	Hold	5	–	–	﹤0.01%	570
2017 Q1	$780	Sell	5 -15	-75%	-$2.63K	﹤0.01%	535
2016 Q4	$4.16K	Buy	+20	New	+$4.16K	﹤0.01%	455

Other funds holding CDTX

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Glen Eagle Advisors's CDTX Position: Q3 2018 in Review

Glen Eagle Advisors sold out of Cidara Therapeutics (CDTX) in Q3 2018, closing a stake of 5 shares — an estimated $520 sold.

Glen Eagle Advisors first reported a position in CDTX in Q4 2016 and held it in 7 quarters. The position peaked at $4.16K in Q4 2016. 59 funds tracked by Wall St. Rank hold CDTX as of Q3 2018.

Glen Eagle Advisors reported no remaining Cidara Therapeutics position as of Q3 2018 after selling out during the quarter.
Glen Eagle Advisors sold 5 Cidara Therapeutics shares in Q3 2018, an estimated $520.
Glen Eagle Advisors first reported a position in Cidara Therapeutics in Q4 2016 and held it in 7 quarters.
Glen Eagle Advisors's Cidara Therapeutics position peaked at $4.16K in Q4 2016.
59 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2018.

Based on Glen Eagle Advisors's 13F filing for Q3 2018, filed 13 Aug 2024.